Extracellular targeted protein degrader removes antibodies in first test in humans

IF 101.8 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nature Reviews. Drug Discovery Pub Date : 2024-06-18 DOI:10.1038/d41573-024-00103-6

Asher Mullard

引用次数: 0

Abstract

Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader. Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在首次人体试验中，细胞外靶向蛋白降解器清除了抗体。

Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平--首次临床验证了小分子细胞外蛋白降解剂的潜力。Biohaven 的 BHV-1300 降低了健康志愿者血液中免疫球蛋白 G 的水平，首次在临床上展示了小分子细胞外蛋白降解剂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.

期刊最新文献

PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial. 2025's FDA approvals by regulatory designations. GSK pays US$2 billion for prophylactic food allergen antibody. Unlocking the potential of disease prevention through regulatory science. Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.